objectives To investigate whether high-dosed folate supplements might diminish the efficacy of malaria intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) in a cohort of pregnant women in Benin, where malaria is holoendemic.
Introduction
Gestational anaemia is the first cause of morbidity in pregnancy worldwide. Anaemia is defined by WHO as a blood haemoglobin concentration < 110 g/l for pregnant women, and severe anaemia is defined as a blood haemoglobin concentration < 70 g/l [1] . According to the latest WHO report in 2011, there were 528.7 million pregnant women (95% CI 440; 629.4) who were anaemic worldwide, which corresponds to a prevalence of 29.4% (95% CI 24.5; 35) [2] . Nutritional deficiencies and pregnancyassociated malaria (PAM) are the main causes of gestational anaemia globally. As a consequence, WHO recommends 200 mg ferrous sulphate and 0.4 mg folic acid daily to fight gestational anaemia [3] . Folic acid supplements are also recommended to prevent neural tube defects. In parallel, WHO recommends an intermittent preventive treatment in pregnancy (IPTp) of 1500/75 mg sulphadoxine-pyrimethamine (SP) at each antenatal care visit (ANV), including at least three doses, starting as early as possible in the second trimester to tackle PAM and its effects [4] .
However, the Ministry of Health in Benin recommends 5 mg of folic acid per day, which corresponds to doses 10 times higher than WHO-recommended ones (0.4 mg daily).
In Benin, the prevalence of gestational anaemia is >60% [5] . Nutritional deficiencies, intestinal helminths and pregnancy-associated malaria (PAM) are its main causes [5] . SP is an antifolate drug, and in some studies, high doses of folic acid supplements have been associated with reduced efficacy of IPTp [6] [7] [8] [9] , especially in the context of SP resistance, which is the case of Benin [10, 11] .
For these reasons, we wanted to evaluate the effect of high-dosed folic acid supplements on malaria risk during pregnancy in the context of a clinical trial of IPTp with SP vs. mefloquine. Furthermore, we analysed as well the effect of folic acid supplements on gestational anaemia.
Materials and methods

Study design
To evaluate this effect, we analysed during the entire pregnancy haematological and P. falciparum indicators of 318 women who received SP-IPTp in the context of the APEC study (Anemia in Pregnancy: Etiology and Consequences). APEC was an observational study that investigated the risk factors for anaemia in pregnant women and their offspring in three maternities located in the Allada District, a semi-rural region in the north of Cotonou. Further details are presented elsewhere [12] [13] [14] . Briefly, APEC was an observational study nested in the clinical trial 'Malaria in Pregnancy Preventive Alternative Drugs' (MiPPAD). MiPPAD was an IPTp clinical trial that compared the efficacy and safety of mefloquine compared to SP ('http://clinicaltrials.gov/ct2/show/NCT00811421'). At the time of the study, there were only two ANV in Benin. Therefore, only two doses of IPTp were given to the pregnant women. The APEC study followed the first 1000 pregnant women included in the MIPPAD cohort of from January 2010 until May 2012. Of these, 318 received SPIPTp and 614 received mefloquine-IPTp according to the MIPPAD randomisation plan (68 of the mefloquine arm were lost to follow-up). A total of 302 of the 318 pregnant women included at baseline who received SP-IPTp completed the follow-up. In this article, we focus solely on pregnant women who received SP-IPTp. For reference, there were no significant differences in low birthweight (LBW), anaemia, placental malaria rates or parasite density between women receiving SP-IPTp and women receiving mefloquine-IPTp in Benin [13] .
Participants and ethical aspects
In Allada, malaria transmission is perennial even if there are two transmission peaks during the rainy seasons in April-July and October-November. The inclusion criteria for the women were as follows: no intake of SP, iron, folic acid, vitamin B12 or anti-helminthic treatment. The Ethics Committee of the Faculty of Medicine of Cotonou supervised and approved the APEC and the MIPPAD studies. Women were informed in their local language about the follow-up conditions of the study before obtaining informed consent.
IPTp and supplement administration
Pregnant women were followed through two systematic antenatal visits (ANV) and unscheduled visits in case of sickness. At the first ANV, pregnant women were included and they were given an ITN as well. They underwent a complete medical examination, and their clinical and gynaecological histories were recorded. IPTp was given at each systematic ANV by the method of direct observation. More precisely, two-dose IPTp (1500/75 mg of SP per dose) was administered one month apart, following the recommendations of the Ministry of Health in Benin. If the woman was included after 15 weeks of gestation, IPTp was also given during the first ANV visit.
Women were also systematically given supplementary preventive therapies to take at home: 600 mg of albendazole for a 3-day treatment, oral ferrous sulphate (200 mg/day) and folic acid (5 mg/day). In case of anaemia (defined in Benin by Hb concentration < 110 g/l), women were treated with 200 mg of oral ferrous sulphate twice a day if they had mild or moderate anaemia (Hb 70-110 g/l). If they had severe anaemia (Hb < 70 g/l), they were referred to the reference hospital. In case of sickness, women came to the maternity clinic, where they were examined and treated if necessary. At each visit, including ANV, unscheduled visits and delivery, clinical and socio-demographic data were recorded. Blood tests (8 ml of venous blood) were performed at ANV1, ANV2 and at delivery. Haemoglobin, serum ferritin, CRP, vitamin B12, lead and seric folate levels were thereby analysed.
Sampling and diagnostic tests
To assess the presence of intestinal helminths, a container was given to the women for stool collection. To investigate the prevalence of placental malaria, a placental blood smear examination was performed at delivery.
Further details on the study sample techniques are presented in detail in our previous article [12] . Briefly, the Lambar en e method [15] was used to determine malaria infection and the Kato-Katz technique for helminthic infections. AxSYM (AxSYM, Abbott Diagnostic, USA) was used to determine serum concentrations of ferritin, folate and vitamin B12. It uses a microparticulate enzyme immunoassay method (MEIA) to determine ferritin and vitamin B12 serum concentrations, and an ion capture technique to quantify serum folate concentration.
To estimate the anopheline risk, we calculated the mean rainfall of the week prior to the 14 days before the consultation. We performed a multiple correspondence analysis plotting all socio-economic items and then predicted a value that corresponds to the socio-economic index.
Data analysis
Clinical and socio-economic data were entered into the database by two data managers. Data were analysed using STATA 12.0 (Stata Corp, College Station, TX, USA). First, we estimated the factors associated with a positive blood smear using univariate analyses. Then, we used univariate analyses to determine risk factors for maternal peripheral parasite density as well as for gestational anaemia. In all analyses, we used multilevel models with a random intercept at the individual level including all visits for each patient (systematic and unscheduled). The variables with P-values < 0.2 were then included in the multivariate models. We used random coefficient models as they were statistically better according to Akaike information criterion (AIC) and Bayesian information criterion (BIC) compared to fixed effects. The AIC and BIC compare maximal-likelihood models. Due to their importance in literature, we forced the socio-economic status and rainfall into the malaria models. The presented P-values and the significance thresholds were two-sided, P < 0.05.
Results
Malaria incidence
During the follow-up period, 98 (30.8%) of the women had at least one malarial episode. The range of positive smears was 0-9. More precisely, 71 (22.3%) of the women had 1 positive smear, 15 (4.7%) had two, and 12 (3.8%) had 3 or more positive blood smears. Sixteen women were lost to follow-up during pregnancy (5.0%). The main characteristics of the cohort are described in Table 1 .
Twenty-nine women had placental malaria (8.5%). The proportion of women with anaemia (haemoglobin < 11 g/dl) fell from 220 (69.2%) at ANV1 to 206 (66.9%) at ANV2 and then to 126 (43.8%). Anaemia at delivery is significantly reduced compared to baseline (adjusted odds ratio (aOR) of anaemia risk at the last antenatal visit compared to baseline = 0.1; Pvalue < 0.001), but the reduction was not significant after the first antenatal visit (aOR compared to inclusion = 0.7; P-value = 0.2). The first two antenatal visits take place during the second trimester, a period of haemo-expansion due to the ongoing angiogenic processes.
Folate and ferritin levels
Other parameters associated with anaemia and nutrition, such as folate or ferritin, varied significantly between pregnancy periods. After the first iron supplements given at ANV1, mean ferritin levels dropped from 36.9 mg/l (95% CI: 31.8; 42.1) to 25.5 mg/l (95% CI: 22.0; 29.0) at the second ANV. At delivery, they were significantly higher: 60.5 mg/l (95% CI: 51.6; 69.4). Similarly, folate deficiency rates dropped significantly after ANV1 from 32.7% to 18.2% at ANV2 (P-value < 0.001) after folate supplement intake, but they were also higher at delivery (43.0%; (P-value = 0.4)).
Folate levels (in base 10 logarithm) were not associated with increased malaria risk aOR = 0.5 (95% CI: 0.2; 1.6, P-value = 0.2), nor with increased P. falciparum density beta coefficient = À0.26 (95% CI: À0.5; 0.02, P-value = 0.07) ( Table 2 ). There were no significant differences in Plasmodium falciparum parasitaemia during the entire follow-up between women with high and women with low folate levels at inclusion, and neither were there statistical differences in malaria risk compared to women who received mefloquine.
On the contrary, higher iron levels were statistically linked to increased odds of PAM. Indeed, higher iron levels (corresponding to the log10 of ferritin corrected on inflammation) were significantly correlated with a higher risk of a positive blood smear (aOR = 1.7 95% CI (1.2; 2.3), P-value < 0.001) during the entire follow-up in a logistic multivariate model. In parallel, higher iron levels were also statistically associated with higher P. falciparum parasite density (beta coefficient = 0.2 95% CI (0.1; 0.3), P-value < 0.001) during pregnancy in linear mixed multivariate models. Inflammatory status and young maternal age were also significantly linked to increased malarial risk including both the possibility of having a positive smear and higher parasite density (Table 3) .
Discussion
In our study, folate levels were significantly associated with reduced risk of anaemia during pregnancy, even after considering the physiologic processes of haemo-dilution and haemo-concentration of a normal pregnancy. In parallel, folate levels were not statistically correlated with increased malaria risk in the context of IPTp and highly dosed folic acid supplements in this cohort. Even though folic acid supplements were given for home intake, we can suppose there has been a good compliance of the treatment as folate deficiency decreased significantly after the intake of these supplements. The slight increase at delivery might be due to the long period between the last folic acid supplement intake and the delivery. Indeed, folic acid supplements are taken until 12 weeks of gestation, following WHO recommendations.
Folic acid is essential and humans cannot synthesise folates de novo. The human body needs folic acid to synthesise DNA, repair DNA and methylate DNA as well as to act as a cofactor in certain biological reactions. Periconceptual folic acid prevents also neural tube defects. Therefore, pregnant women require satisfactory levels of folic acid to produce healthy red blood cells and prevent anaemia. An article gathering evidence from a large randomised controlled trial performed between 1966 and 1967 and from trials included in a Cochrane review found that folic acid at high doses is associated with reduced risk of low birthweight (pooled relative risk 0.73 (95% CI: 0.53, 0.99)) [16] . However, epidemiologic For continuous variables, the mean is provided followed by the 95% confidence interval in parentheses. For categorical variables, n is presented followed by the % in parentheses. studies on the topic are scarce and evidence from malaria-endemic settings in the context of SP-IPTp differs among studies. In Kenya, a study published in 2005 found increased risk of parasitological failure among patients of all ages with uncomplicated P. falciparum malaria and treated with iron, even if there was no evident effect on the risk of clinical failure [7] . With regard to the effect on pregnant women, a trial conducted in Kenya in 2004 on 476 pregnant women to assess the effect of folate supplementation on SP failure found that high-dosed (5 mg daily) folate supplementation or high folate levels at day 7 were independent risk factors for SP failure [9] . More precisely, high baseline folate levels, high parasite densities and age<20 years were risk factors for SP failure. Therefore, they concluded that pregnant women receiving SP should receive low-/ moderate-dose folic acid supplementation. In contrast, a study conducted in the Gambia in 2002 [17] on 261 primigravidae in the context of SP-IPT and folic acid supplements and low SP resistance found a slightly different effect. It concluded that administration of folic acid to pregnant women did not interfere with the protective effect of SP when used for IPTp, and this among primigravidae who are at higher risk of malaria than multigravidae. This might be due to the fact that the doses of folic acid supplements in this study were lower (500-1500 lg/day). Indeed, a 2013 review on the impact of folic acid supplementation on the efficacy of sulphadoxine/pyrimethamine in preventing malaria in pregnancy concluded that the effect of folic acid supplementation on antifolate efficacy is dose-dependent, and folic acid doses required to protect pregnant women from neural tube defects will not decrease antifolate activity [18] .
Although the dose recommended by the Beninese Ministry of Health (5 mg/day) might be excessive, in our study high folate levels in blood are neither associated with an increased incidence of malaria nor with higher P. falciparum parasite density, as described in the literature review. Furthermore, in the same cohort, when considering both SP and mefloquine-IPTp, high folate levels were associated with reduced malaria risk [14] . In addition, our study shows the utility of folate supplements for the prevention of anaemia. Indeed, SP is the most-used IPTp regime worldwide, especially in regions with high anaemia rates. Consequently, it is possible that interference with IPTp entails major consequences for public health. In this context, showing that folate supplement is not associated with an increased malaria risk, but to a reduced risk of anaemia, is interesting for public health policy interventions. Indeed, the dose recommended by WHO might be sufficient to prevent neural tube defects without affecting SP-IPTp efficacy [18] .
A further interesting aspect of the study is the significant association of high iron levels with increased malaria risk in this prospective longitudinal cohort, with regard to the possibility of having a positive blood smear and P. falciparum parasite density. Iron levels, measured by ferritin corrected for inflammation, were significantly associated with malarial episodes and P. falciparum density throughout the pregnancy in the context of IPTp and ITN use [14] . In literature on the malaria-iron association [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , observational studies report some protection of iron supplementation against malaria among iron-deficient children, while older clinical trials report increased susceptibility to malaria among iron-supplemented children. However, iron supplements were not significantly associated with increased malaria risk in recent clinical trials or in a 2016 Cochrane review [27] .
Indeed, evidence of an iron-malaria association is limited by the protective effect of control interventions, the limited follow-up of children and the lack of homogeneous iron indicators. Considering that iron might have a deleterious effect on malaria risk, it is particularly valuable that other interventions to fight anaemia, such as folate supplements, are not associated with higher malaria incidence.
Conclusion
Preventive public health strategies during pregnancy in West African countries include antihelminthic treatment, SP-IPTp to prevent pregnancy-associated malaria and its consequences, but also folic acid and iron supplements to prevent neural tube defects and gestational anaemia. However, folic acid supplements might have an effect on SP, which is an antifolate. According to WHO guidelines, women who have had a foetus diagnosed as affected by a neural tube defect, or who have given birth to a baby with a neural tube defect, should be offered high-dosed supplementation (5 mg folic acid daily). Therefore, it is critical to show that these high folate levels are not associated with increased malarial risk in a prospective longitudinal cohort in the context of both iron and high-dosed folate supplements and IPTp with SP, in a country with increasing resistance to SP. These supplements are associated with reduced risk of anaemia, which is particularly important knowing that iron levels, also given to fight anaemia, are associated with higher malaria risk. In conclusion: high-dosed folic acid supplements are not associated with increased malaria risk in our study, and they contribute to significant reductions of folic acid deficiency and anaemia. However, resistance to SP should be monitored continuously in Benin to evaluate the efficacy of SP against pregnancy-associated malaria.
